Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 3 2Phase 2 2

Status

Unknown 5Completed 2Active not recruiting 2Withdrawn 1Recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Follicular 2Recurrence 1

Interventions

Carboplatin 108Cisplatin 98Paclitaxel 79pembrolizumab 70Gemcitabine 60Pemetrexed 49Cyclophosphamide 48Dexamethasone 47Docetaxel 46durvalumab 44Capecitabine 44Radiotherapy 42Doxorubicin 40Lenalidomide 38Specimen Handling 37Nivolumab 37Oxaliplatin 35Rituximab 34Magnetic Resonance Spectroscopy 33Fluorouracil 33Etoposide 32Bevacizumab 32Vincristine 30atezolizumab 29Radiation 28Leucovorin 28Bortezomib 26Prednisone 23Letrozole 23Fulvestrant 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Active not recruiting × R-CHOP protocol × Clear all
NCT05888493 2026-04-17

LEDA

Novartis

Phase 3 Active not recruiting
109 enrolled
Lymphoid

Lymphoma, Follicular, Recurrence

NCT05058404 2025-09-03

Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Fondazione Italiana Linfomi - ETS

Phase 3 Active not recruiting
605 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡